Deficient FANCL Predisposes to Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension

<b>Rationale:</b> Clinical observations have suggested an association between alkylating agent-based chemotherapy and pulmonary arterial hypertension (PAH). The Fanconi anemia (FA) pathway, the principal mechanism for resolving alkylating agent-induced DNA damage, has been implicated in this process. <b>Objectives:</b> To establish the interplay among the FA pathway, DNA damage, and PAH. <b>Methods:</b> A knockout-first mouse model for FA complementation group L (<i>Fancl</i><sup>kf/kf</sup>) and an adenovirus-associated virus 9-mediated <i>Fancl</i> overexpression (AAV-<i>Fancl</i>) model were used. Lung specimens, pulmonary arterial endothelial cells from patients with PAH, and primarily cultured pulmonary microvascular endothelial cells (PMVECs) from wild-type and <i>Fancl</i><sup>kf/kf</sup> mice were analyzed. <b>Measurements and Main Results:</b> Data analysis on lung single-cell RNA-sequencing datasets revealed significant downregulation of <i>FANCL</i> in endothelial cells from patients with idiopathic PAH, a finding consistently validated in both clinical samples (lung specimens and pulmonary arterial endothelial cells) and the monocrotaline-induced PAH rat model. Notably, <i>Fancl</i><sup>kf/kf</sup> mice developed spontaneous PAH and showed heightened susceptibility to alkylating agent (mitomycin C)-induced PAH, characterized by severe DNA damage and apoptosis in PMVECs. These pathological phenotypes were rescued through <i>Fancl</i> gene supplementation via AAV-<i>Fancl</i> or pharmacological intervention with the DNA damage protector amifostine. Mechanistically, transcriptomic profiling combined with functional validation demonstrated a suppressed bone morphogenetic protein signaling coupled with hyperactivated transforming growth factor-β pathways in PMVECs from <i>Fancl</i><sup>kf/kf</sup> mice. Importantly, this imbalance was fully restored in PMVECs from AAV-<i>Fancl</i>-treated mice. <b>Conclusions:</b> Deficient <i>Fancl</i> plays a key role to promote PAH, and targeted rescue of <i>Fancl</i> could be a novel effective strategy for the treatment of PAH.

Authors

Institutions

Publication Details

Journal
American Journal of Respiratory and Critical Care Medicine
Published
2025-06-13
DOI
https://doi.org/10.1164/rccm.202408-1655oc
Citations
2
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deficient FANCL Predisposes to Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension

Wenju Lu, Ran Xu, Rong Guo, Haiyang Tang et al.
2 citations
American Journal of Respiratory and Critical Care Medicine
Pulmonary Hypertension Research and Treatments
3.04
article

Deficient FANCL Predisposes to Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension

Wenju Lu, Ran Xu, Rong Guo, Haiyang Tang, Shaocong Mo, Kai Yang, Jason X.‐J. Yuan, Yuqi Zhou, Chenting Zhang, Dongyi Xu, Huazhuo Feng, Zizhou Zhang, Xiuzhen Bai, C. Liu, Junqi Zhu, Zifeng Yang, Changlei Bao, Xiaoqian Shan, Shiyun Liu, Jian Wang, Lei Xu, Jiang Qian, Haixia Chen, Jiaxuan Lai, Wei Feng, Haiyun Luo, Yuqin Chen, Xinlin Xu, Yufei Sun, Xiaoyun Luo
article en
2 citations

Abstract

<b>Rationale:</b> Clinical observations have suggested an association between alkylating agent-based chemotherapy and pulmonary arterial hypertension (PAH). The Fanconi anemia (FA) pathway, the principal mechanism for resolving alkylating agent-induced DNA damage, has been implicated in this process. <b>Objectives:</b> To establish the interplay among the FA pathway, DNA damage, and PAH. <b>Methods:</b> A knockout-first mouse model for FA complementation group L (<i>Fancl</i><sup>kf/kf</sup>) and an adenovirus-associated virus 9-mediated <i>Fancl</i> overexpression (AAV-<i>Fancl</i>) model were used. Lung specimens, pulmonary arterial endothelial cells from patients with PAH, and primarily cultured pulmonary microvascular endothelial cells (PMVECs) from wild-type and <i>Fancl</i><sup>kf/kf</sup> mice were analyzed. <b>Measurements and Main Results:</b> Data analysis on lung single-cell RNA-sequencing datasets revealed significant downregulation of <i>FANCL</i> in endothelial cells from patients with idiopathic PAH, a finding consistently validated in both clinical samples (lung specimens and pulmonary arterial endothelial cells) and the monocrotaline-induced PAH rat model. Notably, <i>Fancl</i><sup>kf/kf</sup> mice developed spontaneous PAH and showed heightened susceptibility to alkylating agent (mitomycin C)-induced PAH, characterized by severe DNA damage and apoptosis in PMVECs. These pathological phenotypes were rescued through <i>Fancl</i> gene supplementation via AAV-<i>Fancl</i> or pharmacological intervention with the DNA damage protector amifostine. Mechanistically, transcriptomic profiling combined with functional validation demonstrated a suppressed bone morphogenetic protein signaling coupled with hyperactivated transforming growth factor-β pathways in PMVECs from <i>Fancl</i><sup>kf/kf</sup> mice. Importantly, this imbalance was fully restored in PMVECs from AAV-<i>Fancl</i>-treated mice. <b>Conclusions:</b> Deficient <i>Fancl</i> plays a key role to promote PAH, and targeted rescue of <i>Fancl</i> could be a novel effective strategy for the treatment of PAH.

American Journal of Respiratory and Critical Care MedicineVol. 211(8)
Scripps Research Institute (US), Harvard University (US), Sun Yat-sen University (CN), Peking University (CN), Guangzhou Experimental Station (CN), First Affiliated Hospital of Guangzhou Medical University (CN), Dana-Farber Cancer Institute (US), Third Affiliated Hospital of Sun Yat-sen University (CN), New York Genome Center (US), Guangzhou Medical University Cancer Hospital (CN), State Key Laboratory of Respiratory Disease (CN), Inner Mongolia Medical University (CN), Hubei University (CN), Guangzhou Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 9%
Pulmonary Hypertension Research and Treatments
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.